WO2025120373 - METHODS OF DETERMINING POTENCY OF A HUMAN NEONATAL FC RECEPTOR ANTAGONIST
National phase entry is expected:
Publication Number
WO/2025/120373
Publication Date
12.06.2025
International Application No.
PCT/IB2024/000716
International Filing Date
04.12.2024
Title **
[English]
METHODS OF DETERMINING POTENCY OF A HUMAN NEONATAL FC RECEPTOR ANTAGONIST
[French]
PROCÉDÉS DE DÉTERMINATION DE LA PUISSANCE D'UN ANTAGONISTE DU RÉCEPTEUR FC NÉONATAL HUMAIN
Applicants **
ARGENX BV
Inventors
BORGIONS, Filip
HANSSENS, Valerie
Priority Data
2318512.7
04.12.2023
GB
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3329 | |
| EPO | Filing, Examination, Granting | 32015 | |
| Japan | Filing, Examination, Granting | 3391 | |
| South Korea | Filing, Examination, Granting | 4461 | |
| USA | Filing, Examination, Granting | 12140 |
Total:
55,336
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Methods of determining the potency of a human neonatal Fc receptor (FcRn) antagonist composition in inhibiting the binding of human IgG to FcRn using a competition binding assay are provided. Kits for carrying out said methods, and methods of manufacturing a FcRn antagonist composition comprising said methods of determining potency are also provided.[French]
Sont divulgués des procédés de détermination de la puissance d'une composition antagoniste du récepteur Fc néonatal humain (FcRn) à inhiber la liaison d'une IgG humaine à FcRn à l'aide d'un essai de liaison par compétition. Des kits pour mettre en œuvre lesdits procédés, et des procédés de fabrication d'une composition antagoniste de FcRn comprenant lesdits procédés de détermination de puissance sont aussi divulgués.